Blue water vaccines announces institutional research coverage by two notable healthcare-focused wall street banks, receives “buy” rating from both

Cincinnati, dec. 12, 2022 (globe newswire) -- blue water vaccines inc. (“bwv” or “blue water vaccines” or the “company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced its first analyst coverage since going public in february 2022 with the initial recommendations as “buy” from both maxim group llc (“maxim”) and h.c. wainwright & co. (“h.c. wainwright”) at price targets of $4 and $7, respectively.
BWV Ratings Summary
BWV Quant Ranking